Yeah, it's disappointing. But without facts of what's going on, it's pretty pointless to jump to conclusions.
This delay may be because of mismanagement, or it could be that they are waiting for a catalyst to ensure a better deal is done. Timelines with drug discovery biotechs can be hard to judge too far out.
I would much rather wait for the best deal possible. And I would much rather it's a deal that doesn't need retail involvement. As that has not worked in the past.
In the perfect best case, I would like to see a licence deal (or similiar) for the NK cells (or CarT drugs) where we get an upfront and milestone payments etc. This way, we get the pipeline moving in a non dilutive way. But this is thing dreams are made of. So I am guessing a very low possibility.
Finding someone to throw in double the market cap for a 50% holding would be a hard sell. But this is probably closer to where we might end up ( double market cap may be pie in the sky though). And probably ties in closer to the vote of shares to be allocated that happened earlier this year.
Regardless of how it comes about, CHM needs a hefty money injestion. Its CarT drugs are expensive to develop and trial. We have seen signs that the pipeline seems to be working well. So that has reduced the drug risk. The main risk share holders face are the company financial ones. If this can be overcome, even with large dilution, share holders should be in a good place for a multibag return on investment.
So I am really hoping for a large cash injection. That removes the finance uncertainty and should bring confidence in CHM back to the market. Only then will we start to see the market cap start to reflect the pipeline. Even a large dilution event now would be preferable if the money for a couple of years can be raised. This pipeline vs this Market cap would still make great earnings for shareholders.
This CR is a very important one. It needs to be done correctly. If that takes time, I am all in for waiting.
Add to My Watchlist
What is My Watchlist?
